AGORACOM Small-cap Investor Relations Blog

• Announce the appointment of veteran healthcare industry executive Paul Karam as Sales and Marketing Director, Europe, Middle East & Africa
• Initially, Mr. Karam will be supporting the rollout and expansion in Turkey, Saudi Arabia, The United Arab Emirates and South Africa
• He will also be responsible for new ventures and partnerships across the MEA Region and developing and executing the company marketing strategy in the EMEA region.

MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX), a global leader in teledermatology, is pleased to announce the appointment of veteran healthcare industry executive Paul Karam as Sales and Marketing Director, Europe, Middle East & Africa (“EMEA”), effective immediately. Mr. Karam will be reporting to the Managing Director for the EMEA region and strengthening the MedX global footprint in general and EMEA presence in particular.

Mr. Karam holds a master’s degree in Biomedical Engineering from the University of Surrey in the United Kingdom. He brings 20 plus years of experience in the health care industry, where he has held several leading roles within multinational companies covering Central and Eastern Europe, Turkey, the Middle East, Africa and Pakistan markets. He has a career history with Medtronic, Molnlycke, Stryker, and several other global companies.

“Mr. Karam’s strong experience and skills will be of high added value to our overall strategy in the region, as he helps develop the EMEA region with a specific focus on Turkey, the Middle East and African sub-regions. Mr. Karam will play an integral part in accelerating MedX’s revenue growth prospects by activating his already well-established medical device distributors network to the benefit of MedX’s skin assessment telemedicine technology in the region,” said Mr. Naman Demaghlatrous, Managing Director for EMEA.

Initially, Mr. Karam will be supporting the rollout and expansion in Turkey, Saudi Arabia, The United Arab Emirates and South Africa. He will also be responsible for new ventures and partnerships across the MEA Region and developing and executing the company marketing strategy in the EMEA region.

“We are pleased to welcome Paul to the MedX team. We are fortunate to attract a person of his calibre, and I think it speaks to the strength of our offering and the opportunity it presents in the EMEA market,” stated Michael Druhan, President of Dermatological Services & Products.

Read more: https://agoracom.com/ir/MDX/forums/discussion/topics/756373-medx-health-corp-announces-the-appointment-of-a-sales-and-marketing-director-for-europe-middle-east-africa-emea/messages/2306052#message

• Closed on the final $1.4 million of the $4 million Non-brokered Private Placement of 80 Convertible Debenture Loan Notes
• Each with a face value of $50,000, as originally announced in its Press Release dated January 25, 2021. Previous Closings were announced earlier in February 2021

MedX Health Corp. (“ MedX ” or the “ Company ”) (TSX-V: MDX) is pleased to announce that it has closed on the final $1.4 million of the $4 million Non-brokered Private Placement of 80 Convertible Debenture Loan Notes, each with a face value of $50,000 (“Convertible Notes”), as originally announced in its Press Release dated January 25, 2021. Previous Closings were announced earlier in February 2021.

Full Details of each of the Closings are as follows:

• First Closing on January 27, 2021: $2 million, with cash commissions of $114,000 and issuance of 300,000 Broker Warrants;
• Second Closing on January 28, 2021: $500,000, with cash commissions of $15,000 and issuance of 107,143 Brokers Warrants;
• Third Closing on February 3, 2021: $100,000, with no cash commissions and no Brokers Warrants;
• Fourth, and final Closing, on February 23, 2021: $1.4 million, with cash commissions of $81,000 and issuance of 578,576 Brokers Warrants.

The Convertible Notes will bear interest at 6% per year, payable Quarterly, and will mature on December 31, 2023 (the “Maturity Date”). The Convertible Notes may be converted, at the option of the Holder, into units at $0.14 per unit (“Unit”) at any time until the Maturity Date. Each Unit will be comprised of One (1) fully paid Common Share and One-half (1/2) of a Share Purchase Warrant. Each whole Share Purchase Warrant will be exercisable to purchase One (1) further Common Share at the price of $0.20, exercisable for a period expiring on the Maturity Date. The Convertible Notes, and any underlying securities, are subject to restriction from trading for a period of 4 months and one day from the respective dates of issuance. Qualified Agents received commissions in respect of subscriptions introduced by them by way of cash equal to 6% of funds so introduced, and issuance of agent’s warrants (“Agent’s Warrant(s)”) calculated by reference to 6% of the funds from subscribers introduced by such Agent. Each Agent’s Warrant, which is non-transferable, will be exercisable to acquire one Unit at $0.14 per Unit, at any time during the period up to the Maturity Date. A total of $210,000 of cash commissions were paid, and 985,719 Agent’s Warrants have been issued. The Agent’s Warrants, and any underlying securities, are restricted from trading for a period of four months and one day from their respective dates of issuance.

MedX’s CEO, Rob von der Porten stated, “We believe this financing clearly demonstrates a vote of confidence in our strategic direction and ability to be a leader in the teledermatology space. This funding is significant to furthering the development of our sales initiatives and advancing MedX’s Dermsecure TM platform to a wider global network.”

About MedX

MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin health with its SIAscopy on DermSecure™ telemedicine platform, utilizing its SIAscopy™ technology. SIAscopy is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA, TGA and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union, Turkey and Brazil. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com.

Read More: https://agoracom.com/ir/MDX/forums/discussion/topics/756059-medx-announces-final-closing-of-4-million-convertible-debenture-loan-notes-non-brokered-private-placement/messages/2305336#message